Furthermore, we predict PPARα-mediated adaptations to hepatic lipid overload, shedding light on potential challenges for the use of PPARα agonists to treat NAFLD. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.